- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01400841
HAART Model 300 Annuloplasty Ring
A Prospective, Non-randomized, Multi-center Trial to Evaluate the Safety and Effectiveness of the HAART Model 300 Annuloplasty Ring When Used to Surgically Repair a Leaking Aortic Valve Using a 3-D Intra-annular Mounting Frame
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aortic Regurgitation, (also known as Aortic Insufficiency; AI), is the failure of the aortic valve to close completely during diastole which causes blood to flow from the aorta back into the left ventricle. Aortic Regurgitation (AR) is a frequent cause of both disability and death due to congestive heart failure, primarily in individuals forty or older, but can also occur in younger populations.
Traditionally management of aortic regurgitation has been by aortic valve replacement, however, as has been observed in patients who have had mitral valve repair, the option of maintaining ones native aortic valve versus a replacement, either bioprosthetic or mechanical, can have added multiple benefits. The advantage of repair is the avoidance of prosthetic valve-related complications with bioprosthetic valves over 10-15 years or the need for anticoagulation with mechanical valves and the related problems of this therapy. Therefore, potentially aortic valve repair is a good option for patients with AR or AI.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, B-3000
- University Hospital Gasthuisberg
-
-
-
-
-
Prague, Czech Republic, 1958/9
- Institut klinicke a experimantalni mediciny
-
-
-
-
-
Berlin, Germany, 13353
- German Heart Institute
-
Munich, Germany, 80636
- German Heart Center Munich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is 50 years old or older
- The subject has a tricuspid aortic valve morphology
- Patients with documented severe aortic insufficiency with aortic annular dilation without severe concomitant aortic stenosis
- Patients referred to center for documented moderate to severe Chronic aortic regurgitation (AR) associated with annular dilatation with or without cusp prolapse of one, two, or all three leaflets
- Patients with or without Sinotubular Junction (STJ) dilatation or aortic root aneurysms
- Patients who are free of coronary disease or those with evidence of minor stable (1-2 vessel) coronary disease
- Subject is willing to comply with specified follow-up evaluations, including transesophageal echocardiography if there are inadequate images by transthoracic echocardiography (TTE) to assess the aortic valve
- The subject has signed the written informed consent
- The subject agrees to return for all follow-up evaluations for the duration of the study (i.e. geographically stable
- The subject is New York Hospital Association (NYHA) class II or III
Exclusion Criteria:
- The subject has preexisting valve prosthesis in the atrial, the mitral, pulmonary, and/or tricuspid position
- The subject requires an additional valve replacement
- The subject's aortic valve morphology is not tricuspid
- The subject has active endocarditis
- Heavily calcified valves
- Valvular retraction with severely reduced mobility
- The subject has mixed stenosis and regurgitation of the aortic valve with predominant stenosis
- The subject requires a repair of the mitral or tricuspid valve with the use of an annuloplasty device
- Leukopenia
- Acute anemia (Hb < 9mg%)
- Platelet count <100,000 cell/mm3
- Need for emergency surgery for any reason
- History of bleeding diathesis or coagulopathy or the subject refuses blood transfusions
- Active infection requiring antibiotic therapy (if temporary illness, subjects may enroll 4 weeks after discontinuation of antibiotics)
- Subjects in whom transesophageal echocardiography (TEE) is contraindicated
- Non elective presentation
- Low Ejection Fraction (EF) EF < 40%
- Life expectancy < 1 year
- Rheumatic disease
- The subject has severe leaflet fenestration or leaflets damaged by endocarditis
- The subject is or will be participating in a concomitant research study of an investigational product or has participated in such a study within the 30 days prior to screening
- The subject is a minor, an illicit drug user, alcohol abuser, prisoner, institutionalized, or is unable to give informed consent
- The subject is pregnant or lactating
- This patient will not agree to return to the implant center for the required number of follow-up visits or is geographically unavailable for follow-up
- The subject has not signed and dated the study informed consent
- Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA)
- Myocardial infarction (MI) within one month of trial inclusion
- Have a known intolerance to titanium or polyester
- Sole therapy for correction for patients with aortic root aneurysm
- Subjects requiring simultaneous cardiac procedures
- The subject has asymptomatic AR and a left ventricular ejection fraction (LVEF) > 50%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAART 300 Annuloplasty Device
Implantation of HAART 300 Annuloplasty Device for aortic valve repair
|
Implantation of device for aortic valve repair
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Safety Outcome Measure: Event-free Survival
Time Frame: 1 month postprocedure
|
Event-free survival is defined as survival free from device-related death
|
1 month postprocedure
|
Primary Safety Outcome Measure: Event-free Survival
Time Frame: 2 years postprocedure (extended follow-up)
|
Event-free survival is defined as survival free from device-related death
|
2 years postprocedure (extended follow-up)
|
Primary Efficacy Outcome Measure: Aortic Valvular Regurgitation at 6 Months Postprocedure
Time Frame: 6 months postprocedure
|
Aortic valvular regurgitation assessed by transthoracic echocardiography and graded as None/Trace (0), Mild (1+), Moderate (2+), Moderate-to-Severe (3+), or Severe (4+)
|
6 months postprocedure
|
Primary Efficacy Outcome Measure: Aortic Valvular Regurgitation at 2 Years Postprocedure
Time Frame: 2 years postprocedure (extended follow-up)
|
Aortic valvular regurgitation assessed by transthoracic echocardiography and graded as None/Trace (0), Mild (1+), Moderate (2+), Moderate-to-Severe (3+), or Severe (4+)
|
2 years postprocedure (extended follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
New York Heart Association (NYHA) Functional Capacity Classification
Time Frame: 6 months postprocedure
|
Four classes describing the effect of cardiac disease on physical activity: Class I - disease does not limit activity; Class II - slight limitation; Class III - marked limitation; Class IV - inability to carry out any physical activity without discomfort
|
6 months postprocedure
|
Implant Procedure Success
Time Frame: discharge or 14 days postprocedure, whichever comes first
|
Success is defined as the absence of specified adverse events evaluated through discharge or 14 days after the procedure:
|
discharge or 14 days postprocedure, whichever comes first
|
Implant Procedure Success
Time Frame: 2 years postprocedure (extended follow-up)
|
Success is defined as the absence of specified adverse events evaluated through discharge or 14 days after the procedure:
|
2 years postprocedure (extended follow-up)
|
Actuarial Freedom From Clinical Cardiovascular Events
Time Frame: 1 month postprocedure
|
Freedom from specified clinical cardiovascular events 1 month postprocedure:
|
1 month postprocedure
|
Actuarial Freedom From Clinical Cardiovascular Events
Time Frame: 2 years postprocedure
|
Freedom from specified clinical cardiovascular events 2 years postprocedure:
|
2 years postprocedure
|
Event-free Survival
Time Frame: 6 months postprocedure
|
Event-free survival is defined as survival free from device-related death
|
6 months postprocedure
|
New York Heart Association (NYHA) Functional Capacity Classification
Time Frame: 2 years postprocedure (extended follow-up)
|
Four classes describing the effect of cardiac disease on physical activity: Class I - disease does not limit activity; Class II - slight limitation; Class III - marked limitation; Class IV - inability to carry out any physical activity without discomfort
|
2 years postprocedure (extended follow-up)
|
Peak Gradient - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Transthoracic echocardiography parameter
|
Baseline, 6 months postprocedure
|
Peak Gradient - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Transthoracic echocardiography parameter
|
Baseline, 2 years postprocedure (extended follow-up)
|
Mean Gradient - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Transthoracic echocardiography parameter
|
Baseline, 6 months postprocedure
|
Mean Gradient - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Transthoracic echocardiography parameter
|
Baseline, 2 years postprocedure (extended follow-up)
|
LV Mass - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Left ventricular mass.
Transthoracic echocardiography parameter.
|
Baseline, 6 months postprocedure
|
LV Mass - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Left ventricular mass.
Transthoracic echocardiography parameter.
|
Baseline, 2 years postprocedure (extended follow-up)
|
LVID Diastole - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Left ventricular internal dimension.
Transthoracic echocardiography parameter.
|
Baseline, 6 months postprocedure
|
LVID Diastole - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Left ventricular internal dimension.
Transthoracic echocardiography parameter.
|
Baseline, 2 years postprocedure (extended follow-up)
|
LVID Systole - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Left ventricular internal dimension.
Transthoracic echocardiography parameter.
|
Baseline, 6 months postprocedure
|
LVID Systole - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Left ventricular internal dimension.
Transthoracic echocardiography parameter.
|
Baseline, 2 years postprocedure (extended follow-up)
|
LV Diastolic Volume - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Left ventricular diastolic volume.
Transthoracic echocardiography parameter.
|
Baseline, 6 months postprocedure
|
LV Diastolic Volume - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Left ventricular diastolic volume.
Transthoracic echocardiography parameter.
|
Baseline, 2 years postprocedure (extended follow-up)
|
LV Systolic Volume - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Left ventricular systolic volume.
Transthoracic echocardiography parameter.
|
Baseline, 6 months postprocedure
|
LV Systolic Volume - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Left ventricular systolic volume.
Transthoracic echocardiography parameter.
|
Baseline, 2 years postprocedure (extended follow-up)
|
LVEF - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Left ventricular ejection fraction.
Transthoracic echocardiography parameter.
|
Baseline, 6 months postprocedure
|
LVEF - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Left ventricular ejection fraction.
Transthoracic echocardiography parameter.
|
Baseline, 2 years postprocedure (extended follow-up)
|
Cardiac Output - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Stroke volume x heart rate.
Transthoracic echocardiography parameter.
|
Baseline, 6 months postprocedure
|
Cardiac Output - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Stroke volume x heart rate.
Transthoracic echocardiography parameter.
|
Baseline, 2 years postprocedure (extended follow-up)
|
Cardiac Index - Change From Baseline
Time Frame: Baseline, 6 months postprocedure
|
Hemodynamic parameter computed as cardiac output divided by body surface area
|
Baseline, 6 months postprocedure
|
Cardiac Index - Change From Baseline
Time Frame: Baseline, 2 years postprocedure (extended follow-up)
|
Hemodynamic parameter computed as cardiac output divided by body surface area
|
Baseline, 2 years postprocedure (extended follow-up)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christof Stamm, M.D., German Heart Institute
Publications and helpful links
General Publications
- Mazzitelli D, Fischlein T, Rankin JS, Choi YH, Stamm C, Pfeiffer S, Pirk J, Detter C, Kroll J, Beyersdorf F, Griffin CD, Shrestha M, Nobauer C, Crooke PS, Schreiber C, Lange R. Geometric ring annuloplasty as an adjunct to aortic valve repair: clinical investigation of the HAART 300 device. Eur J Cardiothorac Surg. 2016 Mar;49(3):987-93. doi: 10.1093/ejcts/ezv234. Epub 2015 Jul 8.
- Mazzitelli D, Stamm C, Rankin JS, Pfeiffer S, Fischlein T, Pirk J, Choi YH, Detter C, Kroll J, Beyersdorf F, Shrestha M, Schreiber C, Lange R. Leaflet reconstructive techniques for aortic valve repair. Ann Thorac Surg. 2014 Dec;98(6):2053-60. doi: 10.1016/j.athoracsur.2014.06.052. Epub 2014 Dec 1.
- Mazzitelli D, Stamm C, Rankin JS, Nobauer C, Pirk J, Meuris B, Crooke PS, Wagner A, Beavan LA, Griffin CD, Powers D, Nasseri B, Schreiber C, Hetzer R, Lange R. Hemodynamic outcomes of geometric ring annuloplasty for aortic valve repair: a 4-center pilot trial. J Thorac Cardiovasc Surg. 2014 Jul;148(1):168-75. doi: 10.1016/j.jtcvs.2013.08.031. Epub 2013 Oct 8.
- Mazzitelli D, Nobauer C, Rankin JS, Badiu CC, Dorfmeister M, Crooke PS, Wagner A, Schreiber C, Lange R. Early results of a novel technique for ring-reinforced aortic valve and root restoration. Eur J Cardiothorac Surg. 2014 Mar;45(3):426-30. doi: 10.1093/ejcts/ezt407. Epub 2013 Aug 19.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BSE 300
- TP-01-013 (Other Identifier: Biostable Science & Engineering, Inc)
- TP-01-023 (Other Identifier: Biostable Science & Engineering, Inc)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Regurgitation
-
Imperial College LondonAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)UnknownHeart Valve Diseases | Aortic Valve Insufficiency | Paravalvular Aortic Regurgitation | Regurgitation, AorticNetherlands
-
Centre Chirurgical Marie LannelongueCompletedCardiac Catheterization | Cardiac Valve Disease | Paravalvular Aortic Regurgitation | Paravalvular Mitral Regurgitation
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaTerminatedAortic Regurgitation | Aortic Valve Insufficiency | Regurgitation, Aortic Valve | Aortic Valve | Aortic IncompetenceKorea, Republic of
-
Na Homolce HospitalCentre of Cardiovascular and Transplantation Surgery, Czech Republic; St. Anne... and other collaboratorsRecruitingAortic Valve RegurgitationSerbia, Czechia, Belgium
-
Abbott Medical DevicesEnrolling by invitationParavalvular Aortic RegurgitationUnited States, Spain, Netherlands, Canada, Italy, Poland, United Kingdom
-
Assistance Publique - Hôpitaux de ParisUnknownPure Aortic RegurgitationFrance
-
Genesis Medtech CorporationRecruiting
-
Centre Chirurgical Marie LannelongueEasy-CRFRecruitingQuality of Life | Cardiac Valve Disease | Outcomes | Paravalvular Aortic Regurgitation | Paravalvular Mitral Regurgitation | Paravalvular LeakBelgium, France, Poland, United Kingdom, Czechia, Greece, Italy, Latvia, Lithuania, Mexico, Spain, Turkey
-
UMC UtrechtTerminatedPeriprosthetic Aortic Valve Regurgitation After TAVINetherlands
-
Michele De BonisCompletedAortic Regurgitation | Functional Mitral RegurgitationItaly
Clinical Trials on HAART 300 Annuloplasty Device
-
Biostable Science & EngineeringCompletedAortic InsufficiencyGermany, Czech Republic
-
Biostable Science & EngineeringCompleted
-
Micro Interventional DevicesRecruitingTricuspid RegurgitationDenmark, Poland, Hungary, Latvia, Lithuania
-
Edwards LifesciencesCompletedMitral Valve InsufficiencyItaly, Belgium
-
CytoSorbents, IncCytoSorbents Europe GmbHCompleted
-
Imperial College LondonUMC Utrecht; CytoSorbents, IncUnknownHeart FailureUnited Kingdom
-
Technical University of MunichUnknownRenal Insufficiency or Renal Failure &or End-stage Renal DiseaseGermany
-
CytoSorbents, IncTerminatedBleeding | Emergent Cardiothoracic Surgery | Drug RemovalUnited Kingdom
-
Buddhist Tzu Chi General HospitalRecruitingMuscle Weakness | Strain of Fascia of Intrinsic Muscle of Foot (Disorder) | ElastographyTaiwan
-
Koc University HospitalCompletedErector Spinae Plane Block | Renal Transplantation | Laparoscopic NephrectomyTurkey